Islet specific Wnt activation in human type II diabetes.

51Citations
Citations of this article
51Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The Wnt pathway effector gene TCF7L2 has been linked to type II diabetes, making it important to study the role of Wnt signaling in diabetes pathogenesis. We examined the expression of multiple Wnt pathway components in pancreases from normal individuals and type II diabetic individuals. Multiple members of the Wnt signaling pathway, including TCF7L2, Wnt2b, beta-catenin, pGSK3beta, TCF3, cyclinD1, and c-myc, were undetectable or expressed at low levels in islets from nondiabetic individuals, but were also upregulated specifically in islets of type II diabetic patients. Culture of pancreatic tissue and islet isolation led to Wnt activation that was reversed by the Wnt antagonist sFRP, demonstrating that Wnt activation in that setting was due to soluble Wnt factors. These data support a model in which the Wnt pathway plays a dynamic role in the pathogenesis of type II diabetes and suggest manipulation of Wnt signaling as a new approach to beta-cell-directed diabetes therapy.

Cite

CITATION STYLE

APA

Lee, S. H., Demeterco, C., Geron, I., Abrahamsson, A., Levine, F., & Itkin-Ansari, P. (2008). Islet specific Wnt activation in human type II diabetes. Experimental Diabetes Research, 2008, 728763. https://doi.org/10.1155/2008/728763

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free